A Multicenter, Open Label Study Of Oral Revlimid And Prednisone (Rp) Followed By Oral Revlimid Melphalan And Prednisone (Mpr) In Newly Diagnosed Elderly Multiple Myeloma Patients.

Trial Profile

A Multicenter, Open Label Study Of Oral Revlimid And Prednisone (Rp) Followed By Oral Revlimid Melphalan And Prednisone (Mpr) In Newly Diagnosed Elderly Multiple Myeloma Patients.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Melphalan (Primary) ; Prednisone (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 31 Jul 2017 Planned End Date changed from 1 Aug 2017 to 1 Aug 2019.
    • 05 Feb 2016 Planned End Date changed from 1 Aug 2013 to 1 Aug 2017 as reported by ClinicalTrials.gov.
    • 24 Mar 2012 Planned number of patients 46 added as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top